Gilead Sciences (GILD) has been seeing a notable upward trend amidst a series of positive developments. The expanding access to its HIV drug and advancement in its HIV and Oncology pipeline have caused investors to react optimally. Several investment firms, including Conning Inc., Fluent Financial LLC, and TFR Capital LLC, have increased their stakes in the company, while Aberdeen Group plc reduced its holdings. Citigroup maintains its Buy recommendation with the price target raised to $135.00, an endorsement mirrored in RBC Capital’s Hold rating. The company's reach to new record highs and the bullish turn from 10 analysts has drawn increased attention. Interest continues to grow with acquisitions by 3Chopt Investment Partners and Callan Family Office, while US Bancorp DE and DAVENPORT divest their shares. Despite some dips, GILD's strong performance continues in Q2 with sales targets beat. Moreover, positive forecasts on GILD's stock price, promising Q2 earnings alongside its HIV drug patent protection, and FDA approval for its preventive therapy, reiterate the vitality of this biotech giant. Gilead also saw success with Biktarvy and is expected to block generics till 2036. However, the stock slid momentarily, which needs to be taken into account by investors.
Gilead Sciences GILD News Analytics from Sat, 08 Mar 2025 08:00:00 GMT to Sat, 11 Oct 2025 17:30:39 GMT -
Rating +8
- Innovation +7
- Information +9
- Rumor -1
